B-CLL

Arix Bioscience PLC: Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021

Retrieved on: 
Monday, December 20, 2021
CD22, Lymphatic system, Doctor of Philosophy, CR, MCL, Conference, CRS, ALL, Blinatumomab, UCL, Safety, Nature Medicine, Adult, EFS, GMT, List of life sciences, University College London, GLOBE, ASH, CAR, Cytokine release syndrome, Society, Royal College of Pathologists, Cell, Nasdaq, COVID-19, Cancer, Rate, CD19, ET, B-CLL, Engineering, Exposition, DLBCL, B-ALL, Real-time, PM, Lymphocytosis, Company, Efficacy, HIV disease progression rates, Toxicity, Cancer Institute, Industry, Patient, MRD, Abstract (summary), CLL, Pharmaceutical industry, Vaccine, Medicine, Health insurance, Wood drying, Medical device, MD, Webcast, Arix Bioscience plc, obe-cel, ARIX BIOSCIENCE PLC, AUTOLUS THERAPEUTICS PLC, OBE-CEL, AUTO1/22

As of the cut-off date of 13 September, 16 patients in the Phase 1b part of the FELIX study had received obe-cel.

Key Points: 
  • As of the cut-off date of 13 September, 16 patients in the Phase 1b part of the FELIX study had received obe-cel.
  • Patient characteristics in the FELIX 1b portion were broadly comparable to those observed in the ALLCAR19 study in r/r adult B-ALL.
  • The company expects to present data from the Phase 2 portion of the FELIX study in 2022.
  • To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus' website.

Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

Retrieved on: 
Monday, December 13, 2021
Therapy, CD22, Lymphatic system, Doctor of Philosophy, CR, MCL, Conference, CRS, ALL, Forward-looking statement, Blinatumomab, UCL, Safety, Nature Medicine, Adult, EFS, U.S. Securities and Exchange Commission, Security (finance), GMT, Risk, University College London, GLOBE, ASH, CAR, Cytokine release syndrome, Society, Royal College of Pathologists, Cell, Nasdaq, COVID-19, Cancer, Rate, CD19, ET, B-CLL, Engineering, Exposition, DLBCL, B-ALL, Real-time, PM, Lymphocytosis, Company, Efficacy, HIV disease progression rates, Toxicity, Private Securities Litigation Reform Act, Annual report, American Society of Hematology, Patient, MRD, Abstract (summary), CLL, Vaccine, Pharmaceutical industry, Medicine, Health insurance, Wood drying, Medical device, MD, Webcast

LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, presented further progress on obecabtagene autoleucel (obe-cel) in an oral presentation [Abstract 477] entitled “Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process” at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021. The Company also presented an update of obe-cel in relapsed/refractory aggressive and indolent B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL) patients from the ALLCAR19 extension study, as well as preclinical and initial engraftment data with AUTO1/22 in Pediatric ALL in two separate poster presentations [Abstracts 3823 and 1710, respectively].

Key Points: 
  • Patient characteristics in the FELIX 1b portion were broadly comparable to those observed in the ALLCAR19 study in r/r adult B-ALL.
  • 75% patients in the FELIX Phase 1b had >20% blasts at pre-conditioning, compared with 60% patients in ALLCAR19.
  • The company expects to present data from the Phase 2 portion of the FELIX study in 2022.
  • In collaboration with Autolus academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL.